Juno inks deals with Eli Lilly, the Hutch as it looks to leapfrog leaders on BCMA – Endpoints News
Endpoints News |
Juno inks deals with Eli Lilly, the Hutch as it looks to leapfrog leaders on BCMA
Endpoints News Looking past the CD19 biomarker, BCMA offers one of the most promising targets in CAR-T. Look for this in a clinical trial, coming soon. “BCMA appears to be an important target for treating patients with multiple myeloma and Juno is dedicated to … Juno Therapeutics (JUNO) Reports Licensing Agreements with Lilly (LLY), OncoTracker, and Fred Hutchinson Cancer … Juno inks three agreements to advance program in multiple myeloma; shares ahead 4% premarket |
